relaza2 results: azacitidine use in mds & aml | anne sophie kubasch, md | eha 2024
Published 1 month ago • 41 plays • Length 4:37Download video MP4
Download video MP3
Similar videos
-
3:23
final long-term follow-up results of the relaza2 study: mrd-guided treatment with aza in mds and aml
-
5:22
magrolimab azacitidine in mds and aml
-
2:42
quidel 20299 sofia 2 analyzer
-
0:53
dr. dinardo on rationale to combine enasidenib and azacitidine in aml
-
1:33
phase i trial results for oral azacitidine and venetoclax in r/r aml
-
4:44
establishing the clinical benchmark of azacitidine in patients with mds
-
3:23
genrui sars-cov-2 neutralizing antibody test kit (immunoassay)
-
4:41
acute myeloid leukemia survival rate and outlook
-
1:32:42
mds & covid-19 vaccine
-
1:26
actimab-a update
-
1:56
evaluating long-term survival in patients with aml who discontinued azacitidine-venetoclax
-
0:25
denarase elisa kit for the quantitative analysis of residual 𝘚𝘦𝘳𝘳𝘢𝘵𝘪𝘢 𝘮𝘢𝘳𝘤𝘦𝘴𝘤𝘦𝘯𝘴 endonucleases
-
8:32
quazar: oral azacitidine maintenance in aml
-
2:02
oral azacitidine maintenance in aml with mds-related changes: insights from quazar aml-001
-
1:53
asc2escalate: phase ii dose-escalation study of second-line asciminib in patients with cml-cp
-
2:11
update on phase i/ii study of azacitidine, venetoclax and gilteritinib in patients with flt3 aml
-
1:54
fusion-aml-001: molecular changes associated with azacitidine & durvalumab in tp53m aml and hr-mds
-
1:31
smcxpro: how to reconstitute the il6 standard merck
-
2:21
viale-a trial: should azacitidine plus venetoclax become soc for elderly patients with nd aml?
-
1:15
bio-rad & platelia sars-cov-2 total ab assay
-
1:06
discussing rationale of azacitidine plus maintenance therapy in aml